Zeng Hui Founder of Beijing Lado Technology Co., Ltd. and Chairman of Huidi Kaide (Beijing) Medical Technology Co., Ltd.
Director of the Nuclear Medicine Branch of the Chinese Nuclear Society, Member of the Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association, and Member of the Professional Committee of Nuclear Medicine and Molecular Imaging of the Beijing Nuclear Society.
In 1993, Mr. Zeng founded Beijing Lado Technology Co., Ltd. In 1999, the company launched the first nuclear medicine department reporting system software in China. For many years, he has been committed to the development of nuclear medicine. Leveraging his extensive international resources, he has introduced a number of internationally advanced technologies, integrated them with the Chinese market, and successfully promoted and pioneered many industry-first applications.
One of his most remarkable technology introductions is iHeartsee, licensed from Dr. Gould of the United States, a product dedicated to quantitative myocardial blood flow analysis. It fills the domestic gap in quantitative analysis combining nuclear cardiology and medical imaging, improves the accuracy of cardiac health diagnosis through PET technology, and supports the establishment of an early screening system for cardiovascular diseases in China.
As a private enterprise, his company exclusively introduced German HPP technology and cyclotron equipment, addressing key technical bottlenecks in radiopharmaceutical production and imaging examinations in nuclear medicine. This has promoted the popularization of clinical PET-CT applications in China, reduced the cost of high-end medical examinations, and improved diagnostic efficiency for tumors, neurological disorders, and other diseases.
In 2023, he introduced advanced digital orthopedic solutions from Germany and established Huidi Kaide (Beijing) Medical Technology Co., Ltd. through a joint venture with a German enterprise. By optimizing algorithms and equipment adaptability to fit Chinese clinical requirements and accelerating the product registration process, the company became one of the first domestic entities approved for such technologies, driving the transformation of orthopedic surgery toward precision and intelligence.
